Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Benitec Biopharma Limited
BNTC | US
10.98
USD-0.52
-4.52%
BNTC | US
About Benitec Biopharma Limited
Sector
Healthcare
Industry
Drug Manufacturers-Specialty & Generic
Earnings date
30/06/2024
As of date
20/03/2026
Close
10.98
Open
11.49
High
11.63
Low
10.93
Benitec Biopharma Inc. a development-stage biotechnology company focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301 an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward California.
View LessBNTC | US
Risk
57.4
Sharpe
-0.55
Luna's Score
43/100
Recommendation
Sell
Luna says (BNTC | US)
What's Working
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Strong Revenue Growth (> 10%)
What's not Working
Weakness based on declining price with high volume
Price Below SMA10D
High Short-term Volatility
High Current Volume and Negative 1-Day Return
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
72.7%1 month
57.4%3 months
56.5%6 months
65.0%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
4.25
Debt to equity
0.01
Debt to assets
0.01
Ent. to EBITDA
0.27
Ent. to rev.
10.46K
PEG
-
Other Fundamentals
EBITDA
-22.40M
MarketCap
196.47M
MarketCap(USD)
196.47M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
12.50
Ret. on equity
-91.68
Short ratio
2.67
Short perc.
0.66
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
3.14
Range1M
3.15
Range3M
4.54
Volumes: Market Activity
Rel. volume
3.20
Price X volume
7.87M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.27 | - | Cheaper |
| Ent. to Revenue | 10,457.70 | - | Expensive |
| PE Ratio | - | 30.05 | - |
| Price to Book | 4.25 | 13.15 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 56.48 | - | Par |
| Debt to Equity | 0.01 | -1.88 | Expensive |
| Debt to Assets | 0.01 | 0.48 | Cheaper |
| Market Cap | 196.47M | - | Emerging |
